Definitive Contract 75N93019C00043
Award Date 9/12/19
Potential Completion Date 3/31/26
Potential Value $11M
Federal Agency
Ultimate Awardee
Not listed Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Cost No Fee
Place of Performance
Portland, OR 97239, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
12
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This federal contract award for $18,472,563.99 was issued by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to the University of Montana. The contract's objective is to identify novel adjuvant candidates that can be used to augment the efficacy of human vaccines. Research under this definitive, cost-no-fee contract will contribute to the pipeline of new adjuvant leads that either exploit the innate immune system or act directly...
- The Department of Health and Human Services' National Institute of Allergy and Infectious Diseases (NIAID) awarded a $9,896,692 Vaccine Adjuvant Discovery Program (VADP) contract to the University of Montana. The 5-year contract, which has no set-aside designation, aims to identify, characterize, and advance novel synthetic adjuvants for use in combination with bacterial and fungal antigens to induce a safe and durable T-helper 17 (Th17) and/or Th17/Th1 immune response. The University of Montana...
- This is a $9,013,936.11 cost-no-fee definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health to the Icahn School of Medicine at Mount Sinai. The contract is part of NIAID's Vaccine Adjuvant Discovery Program and aims to identify novel adjuvant candidates that can be used to enhance the efficacy of human vaccines. The contract has no set-aside designation. Key subcontractors include The Scripps Research Institute,...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $6,690,024.90 definitive, cost-no-fee contract to Vaxine PTY LTD, a for-profit organization located in Australia, for an Adjuvant Development Program. The contract, which has an ultimate completion date of February 10, 2025, was awarded on September 10, 2018 and does not have a set-aside designation. The contract aims to support the development of vaccine adjuvants, which are compounds that enhance the immune response to...
- This is a federal contract award from the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to The Leland Stanford Junior University (Stanford University), a private research institution. The $19,155,153 contract is for a 5-year research program to compare multiple vaccine adjuvants and comprehensively assess the immune responses they induce. The goal is to develop "immune fingerprints" of adjuvants using advanced...
- This federal contract award, valued at $9,189,961.00, was granted to Institut De Formulation DES Vaccins (Ch) SA, operating as Vaccine Formulation Institute (Ch) LTD, a for-profit limited liability company based in Switzerland. The contract was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the Department of Health and Human Services, for the Vaccine Adjuvant Discovery Program. This five-year definitive contract, running from September 2024...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $10.3 million definitive cost-no-fee contract to the University of California, San Diego on September 30, 2024, to support the Vaccine Adjuvant Discovery Program (VADP). This five-year effort, which extends through September 2029, is being performed in La Jolla, California. The contract represents a bilateral modification to descope activities for fiscal year 2025 cost savings. No set-aside designation was used in this...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $10.98M definitive contract to The Children's Hospital Corporation, doing business as Boston Children's Hospital, to identify novel adjuvant candidates that can augment the efficacy of human vaccines under the Vaccine Adjuvant Discovery Program. The award, made on September 30, 2019, with an ultimate completion date of December 29, 2025, reflects NIAID's commitment to advancing vaccine development through improved...
- This is a cost-type definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Virovax LLC, a minority-owned limited liability company, for an Adjuvant Development Program. The contract has a ceiling value of $9,273,316.19 and a period of performance through September 29, 2025. The contract was awarded on September 30, 2018 and does not utilize a set-aside designation. As NIAID is the funding agency, this award is likely supporting the...
- This $599,526 Firm Fixed Price contract was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to Enepret Incorporated, a for-profit manufacturer located in Lexington, Kentucky. The contract is for "Adjuvant Discovery and Down-Selection for Vaccines against Infectious and Immune-Mediated Diseases" and supports NIAID's broader program goals related to "A More Durable and Universal Adjuvanted...